Subcutaneous Immunotherapy in Patients Sensitized to Phleum Pratense

Summary

Based on EMA (European Medicines Agency) new guidelines on the clinical development of products for immunotherapy for the treatment of allergic disease the aim of this study was to assess safety and tolerability of three different subcutaneous immunotherapy dose escalations in patients allergic to the pollen of Phleum pratense.

Timeline

Start

2010-01

Primary completion

2010-04

Completion

2010-05

Drugs

Indications